Breaking Down SG&A Expenses: BioMarin Pharmaceutical Inc. vs Ultragenyx Pharmaceutical Inc.

SG&A Expenses: BioMarin vs. Ultragenyx Over a Decade

__timestampBioMarin Pharmaceutical Inc.Ultragenyx Pharmaceutical Inc.
Wednesday, January 1, 201430215600010811000
Thursday, January 1, 201540227100033001000
Friday, January 1, 201647659300064936000
Sunday, January 1, 201755433600099909000
Monday, January 1, 2018604353000127724000
Tuesday, January 1, 2019680924000161524000
Wednesday, January 1, 2020737669000182933000
Friday, January 1, 2021759375000219982000
Saturday, January 1, 2022854009000278139000
Sunday, January 1, 2023937300000309799000
Monday, January 1, 20241009025000
Loading chart...

Cracking the code

A Tale of Two Biotechs: SG&A Expenses Over Time

In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for sustaining growth and innovation. BioMarin Pharmaceutical Inc. and Ultragenyx Pharmaceutical Inc., two prominent players in the industry, have shown distinct trajectories in their SG&A spending from 2014 to 2023. BioMarin's SG&A expenses have surged by over 200%, reflecting its aggressive expansion and market penetration strategies. In contrast, Ultragenyx, while also increasing its SG&A expenses by nearly 2800%, started from a much smaller base, indicating its rapid scaling efforts.

By 2023, BioMarin's SG&A expenses were approximately three times higher than Ultragenyx's, highlighting its established market presence. This comparison not only underscores the different growth stages of these companies but also offers insights into their strategic priorities. As the biotech landscape evolves, monitoring such financial metrics will be key to understanding industry dynamics.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025